Anaphylactic Reaction Clinical Trial
Official title:
A Phase 1 Comparative Bioavailability Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults
This is a study to determine the relative bioavailability of inhaled epinephrine compared with 0.3mg epinephrine administered IM in healthy male and female participants.
DMC-IH1 (Investigational Product) is a capsule containing epinephrine bitartrate dry powder blend contained within a single-use, proprietary inhalation device. The planned dosages for inhalation are 0.3 mg on Visit 2, 1.3 mg (dose will not exceed 6 mg) on Visit 3, and 4 mg (dose will not exceed 6 mg) on Visit 4. The study will comprise 3 periods: Screening, Treatment, and Follow-up. Total duration of the study is approximately 66 days including -28 days from screening to visit to follow up ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT02559960 -
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
|
||
| Recruiting |
NCT05028257 -
Allergy and COVID-19 Vaccines
|
Phase 3 | |
| Not yet recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
Phase 4 | |
| Not yet recruiting |
NCT06013150 -
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.
|
Phase 1 | |
| Recruiting |
NCT03640884 -
Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry Study
|
||
| Completed |
NCT06205134 -
Comparative Bioavailability of Intranasal Epinephrine
|
Phase 1/Phase 2 |